BioSpace News Archive

VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering and improving the healthcare economics, is pleased to announce it will be presenting at Biotech Showcase 2020.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its President, Chairman and Chief Executive Officer, Kevin Hrusovsky, will be presenting on the company’s growth and vision for the fourth consecutive year at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

AOA’s #2020EyeExam encourages Americans to make eye health and vision care a priority in 2020 and beyond

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its development partner, Kaken Pharmaceutical Co. Ltd. (“Kaken”) submitted a new drug application for approval of manufacturing and marketing for sofpironium bromide in Japan for primary axillary hyperhidrosis.

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced a significant investment to expand the presence and capabilities of Janssen Research & Development, LLC, in the San Francisco Bay Area

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1 (PH1).

Editas Medicine, Inc., a leading genome editing company, announced the grant of inducement awards to the Company’s newly appointed Chief Financial Officer, Michelle Robertson.

The Finnish medical technology company Planmed Oy and the UK-based medical X-ray software solutions provider IBEX Innovations Ltd. have signed a collaboration agreement

Kronos Bio, Inc. announced that Norbert Bischofberger, Ph.D., President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 10:30 a.m. Pacific Time.

Novus Therapeutics, Inc. announced the agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate of 5,605,816 shares of common stock having an exercise price of $4.00 issued by the company on May 2, 2019, at a reduced exercise price of $0.84 per share.